Durysta Implant
Product Images NDC 0023-9652
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Durysta (NDC 0023-9652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Durysta 02)
The Structural Formula For Durysta Is An Intracameral Implant Containing 10 Mcg Bimatoprost In The Novadur® Solid Polymer Sustained-release Drug Delivery System (dds). Durysta Is Preloaded Into A Single-use, Dds Applicator To Facilitate Injection Of The Rod-shaped Implant Directly Into The Anterior Chamber Of The Eye. The Components Of The Implant Are Bimatoprost Drug Substance And Polymers Poly (d,l-lactide), Poly (d,l-lactide-co-glycolide), And Polyethylene Glycol. The Chemical Name For Bimatoprost Is (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-n-ethyl-5-heptenamide, And Its Molecular Weight Is 415.57. Its Molecular Formula Is C25h37no4. (Durysta 03)
Figure 3: Study 1 Mean Iop (mmhg) By Treatment Group And Treatment Difference In Mean Iop (Durysta 04)
Figure 4: Study 2 Mean Iop (mmhg) By Treatment Group And Treatment Difference In Mean Iop (Durysta 05)
Principal Display Paneldurystatm(bimatoprost Implant) 10 Mcgndc 0023-9652-01 (Durysta 07)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.